ARCH Venture Partners | Activity | F4

ARCH Venture Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

News

ARCH co-founder Bob Nelsen was named to Forbes' 2026 list of America's most successful living optimists.

ARCH Venture Partners

ARCH Venture PartnersARCH Venture Partners

forbes.comOCT 21, 2026

OCT 21, 2026

Milestone

ARCH-backed City Therapeutics completed a $230M IPO to advance RNAi therapeutics, becoming the 26th biotech IPO of 2026.

City Therapeutics

City Therapeutics ARCH Venture Partners

endpoints.newsOCT 19, 2026

OCT 19, 2026

Investment

ARCH-backed Sentivera launched with $1.5B in financing to develop treatments for inflammatory diseases, founded by the same team behind Metsera.

Sentivera

Sentivera ARCH Venture Partners

fiercebiotech.comAUG 25, 2026

AUG 25, 2026

Milestone

ARCH-backed Kardigan raised $400M in an IPO to fund three clinical-stage cardiovascular programs for dilated cardiomyopathy and other heart conditions.

Kardigan

Kardigan ARCH Venture Partners

biopharmadive.comJUN 17, 2026

JUN 17, 2026

Investment

ARCH Venture Partners participated in SonoThera's $125M Series B to advance ultrasound-mediated nonviral genetic medicines for DMD and ADPKD.

SonoThera

SonoThera ARCH Venture Partners

biospace.comJUN 11, 2026

JUN 11, 2026

Milestone

ARCH-backed Parabilis Medicines set a biotech IPO record with a $670M offering, the largest biotech IPO in history.

Parabilis Medicines

Parabilis Medicines ARCH Venture Partners

wsj.comJUN 10, 2026

JUN 10, 2026

Investment

Co-led CREATE Medicines' $122M Series B to advance its in vivo CAR pipeline in autoimmune disease and oncology; Senior Partner Brian Cuneo joined the board.

CREATE Medicines

CREATE Medicines ARCH Venture Partners

biopharmadive.comMAY 14, 2026

MAY 14, 2026

Milestone

ARCH-backed Seaport Therapeutics debuted on public market with a $225M IPO for neuropsychiatry treatments.

Seaport Therapeutics

Seaport Therapeutics ARCH Venture Partners

fiercebiotech.comMAY 1, 2026

MAY 1, 2026

Milestone

Paradigm Health partnered with the FDA on a real-time clinical trial monitoring platform.

Paradigm Health

Paradigm Health ARCH Venture Partners

archventure.comAPR 2026

APR 2026

News

ARCH partner Carol Suh was honored on the San Francisco Business Times 40 Under 40 Class of 2026.

Carol Suh named to San Francisco Business Times 40 Under 40

ARCH Venture Partners

archventure.comAPR 2026

bizjournals.com

APR 2026

Milestone

ARCH-backed Generate Biomedicines went public with a $400M IPO to accelerate AI-driven drug discovery.

Generate Biomedicines

Generate Biomedicines ARCH Venture Partners

fiercebiotech.comFEB 27, 2026

FEB 27, 2026

3 newss· FEB 2026Show all

News

ARCH Partner Carol Suh was named to the National Venture Capital Association's 2026 List of Rising Stars.

ARCH Venture Partners

ARCH Venture PartnersARCH Venture Partners

linkedin.comFEB 19, 2026

FEB 19, 2026

News

ARCH's Carol Suh was named to NVCA's 2026 Rising Stars list.

Carol Suh named to NVCA 2026 Rising Stars list

ARCH Venture Partners

linkedin.comFEB 19, 2026

FEB 19, 2026

News

ARCH's Carol Suh was named to the National Venture Capital Association's 2026 List of Rising Stars.

Carol Suh named to NVCA 2026 List of Rising Stars

ARCH Venture Partners

archventure.comFEB 2026

FEB 2026

Page 1 of 2